Boston Biomedical Oncology Pipeline

Below is a list of ongoing clinical and preclinical studies involving investigational compounds from Boston Biomedical. Clinical studies link to corresponding pages on clinicaltrials.gov. For more information contact us at info@bostonbiomedical.com.

Napabucasin (also known as BB608, BBI608 or BBI-608)

Napabucasin is an orally administered investigational agent designed to inhibit cancer stem cell pathways by targeting STAT3.
Development Location
Preclinical/ Research
Phase I
Phase II
Phase III

Global

CanStem303C
Colorectal cancer

(Combination therapy)

Global

CanStem111P
Pancreatic cancer

(Combination therapy)

US

Glioblastoma

(Combination therapy)

Canada

Malignant pleural mesothelioma*

(Combination therapy)

Japan

Colorectal cancer

(Combination therapy)

North America

Gastrointestinal cancer

(Combination with standard chemotherapies)

North America

Multiple solid tumors

(NSCLC, ovarian, breast, melanoma)

North America

Hepatocellular carcinoma*

(Combination therapy)

Japan

Hematologic malignancies*

(MM, lymphoma, AML, MDS, CML)

US

Hepatocellular carcinoma

(Combination therapy)

US

Multiple solid tumors

(Combination with BB503)

US

Multiple solid tumors

(Combination with immune checkpoint inhibitors)

US

Pancreatic cancer

(Combination therapy)

US

BB503 (also known as BBI503 or BBI-503)

BB503 is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases.
Development Location
Preclinical/ Research
Phase I
Phase II
Phase III

Canada

Canada

North America

Ovarian cancer*

(Monotherapy)

US

Multiple solid tumors

(Monotherapy, Combination therapy in hepatocellular carcinoma)

Japan

Multiple solid tumors

(Combination therapy)

North America

Hepatocellular carcinoma

(Combination therapy)

US

Multiple solid tumors

(Combination therapy with Napabucasin)

US

Other Oncology Programs

Other Oncology Programs (DSP-7888 is an investigational agent and is not approved by the US FDA.)
Development Location
Preclinical/ Research
Phase I
Phase II
Phase III

Cancer peptide vaccine DSP-7888

(Myelodysplastic syndrome)

Japan

Japan

Cancer peptide vaccine DSP-7888

(Multiple solid tumors and hematologic malignancies)

US

Cancer stem cell pathway inhibitor

Cancer stem cell vaccine

Cancer stemness kinase inhibitor

Immune response modifier

aiRNA targeting cancer stem cell pathways

References

*Active, not recruiting.

Not yet recruiting.